Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).
説明 | GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively). |
ターゲット&IC50 | LXRβ:7.4(pic50), LXRα:7 (pic50) |
In vitro | GSK2033 dose-dependently inhibits basal transcription in full-length LXRα or full-length LXRβ cotransfection assays (IC50s: 17 nM and 9 nM, respectively). GSK2033 also effectively inhibits the transcription of an ABCA1 driven luciferase reporter dose-dependently (IC50s: 52 nM for LXRα and 10 nM for LXRβ). GSK2033 also suppresses the expression of both of fatty acid synthase (FASN) and SREBP1[2]. |
In vivo | GSK2033 (one month) treatment, does not have obviously effects on hepatic triglyceride levels. GSK2033 treatment also have no effects on plasma triglyceride levels[2]. |
分子量 | 591.66 |
分子式 | C29H28F3NO5S2 |
CAS No. | 1221277-90-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (50.70 mM), Sonication and heating are recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK2033 1221277-90-2 Metabolism Liver X Receptor Liver X receptor Inhibitor inhibit LXR GSK-2033 GSK 2033 inhibitor